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Abstract  
Objective 
Variant Ataxia-Telangiectasia is caused by mutations that allow some retained ATM 
kinase activity.  Here, we describe the clinical features of the largest established 
cohort of individuals with variant Ataxia-Telangiectasia and explore genotype-
phenotype correlations. 
Methods 
Cross-sectional data were collected retrospectively. Patients were classified as variant 
Ataxia-Telangiectasia based on retained ATM kinase activity. 
Results 
The study includes 57 individuals. Mean age at assessment was 37.5 years. Most had 
their first symptoms by age ten (81%). There was a diagnostic delay of more than ten 
years in 68% and more than 20 years in a third of probands.   
Disease severity was mild in a third of patients and 43% were still ambulant 20 years 
after disease onset.  Only a third had predominant ataxia and 18% had a pure 
extrapyramidal presentation.  Individuals with extrapyramidal presentations had 
milder neurological disease severity. There were no significant respiratory or 
immunological complications, but 25% of individuals had a history of malignancy. 
Missense mutations were associated with milder neurological disease severity but 
with a higher risk of malignancy, compared to leaky splice site mutations. 
Interpretation 
Individuals with variant Ataxia-Telangiectasia require malignancy surveillance and 
tailored management. However, our data suggest the condition may sometimes be 
mis- or underdiagnosed due to atypical features, including exclusive extrapyramidal 
symptoms, normal eye movements and normal AFP levels in some individuals.  
Missense mutations are associated with milder neurological presentations but a 
particularly high malignancy risk and it is important for clinicians to be aware of 
these phenotypes.  
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Introduction 
Ataxia-Telangiectasia is a rare autosomal recessive disorder caused by mutations in 
the ATM gene on chromosome 11q22.3 (MIM 208900)1.  The ATM protein is a 
serine-threonine protein kinase, which phosphorylates more than 700 substrates and is 
a key player in the cellular response to double stranded DNA damage2. The clinical 
and genetic features of Ataxia-Telangiectasia vary and two forms of the disease have 
been described. 
Classic (or typical) Ataxia-Telangiectasia presents with a severe phenotype and has an 
estimated incidence of 1 in 300, 0003.  Individuals with classic Ataxia-Telangiectasia 
have absent ATM kinase activity4, either due to two null mutations or mutations 
which result in protein without ATM kinase activity.  It is a multisystem 
neurodegenerative disease which also causes immunological defects, respiratory 
problems, oculocutaneous telangiectasia and an increased risk of malignancy5,6. 
Affected children are usually wheelchair bound before teenage and have severe 
neurological disability including cerebellar ataxia, extrapyramidal features, 
oculomotor dyspraxia and polyneuropathy7. Most individuals with classic Ataxia-
Telangiectasia die before the age of 30; malignancy or respiratory failure are the main 
causes of death8,9. 
In addition to classic Ataxia-Telangiectasia a second form, variant Ataxia-
Telangiectasia has been described as a cause of neurological dysfunction10,11. A study 
of 51 patients with A-T (including 9 with retained ATM kinase activity) showed that 
individuals with retained ATM kinase activity have a milder neurological phenotype4.  
Variant Ataxia-Telangiectasia results either from leaky splice site mutations which 
allow expression of some normal ATM protein or missense mutations which produce 
a mutant ATM protein with activity12.  It has been speculated that the presence of 
some ATM kinase activity relates to a milder neurological phenotype and a lower risk 
of systemic complications. Furthermore, a range of atypical neurological 
presentations have been reported to occur in some individuals with variant A-T.   
 
Previously published reports of variant A-T are limited to small cohorts of less than 
15 individuals7,13–16 or case studies of unusual presentations17–21.  
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The true clinical spectrum of variant Ataxia-Telangiectasia is unknown and it is not 
clear which factors determine the extreme clinical variability that has been reported. It 
is unclear whether affected individuals require specific surveillance for systemic 
complications and malignancy, similar to existing management recommendations of 
classic Ataxia-Telangiectasia22,23.  
 
Here, we report the clinical features of the largest established cohort of patients with 
variant Ataxia-Telangiectasia. We provide prognostic information and explore 
genotype-phenotype correlations to inform management guidelines. 
 
Methods 
Probands 
Clinical data were retrospectively collected from case notes for all individuals with 
variant Ataxia-Telangiectasia who have attended the National Adult Ataxia-
Telangiectasia service (Papworth Hospital, UK), the Ataxia-Telangiectasia Specialist 
Centre (Nottingham City Hospital, UK) and the Excellence Centre of Movement 
Disorders (Radboud UMC, Nijmegen, Netherlands).  Analysis includes single cross-
sectional data using the most recent recorded clinical assessment. 
Molecular genetics studies 
Patients were classified as having variant Ataxia-Telangiectasia based on retained 
ATM kinase activity. Patients with a mutation in the initiator methionine codon were 
included because of some uncertainty of ATM activity associated with these 
mutations.  ATM mutations were identified by Sanger sequencing of PCR amplified 
ATM exon sequences.  A lymphoblastoid cell line was derived from each patient’s 
blood and immunoblotting for ATM expression and ATM activity assays were 
performed using methods as previously described24.  Chromosomal radiosensitivity 
was measured following exposure to 1Gy gamma rays at cell cycle phase G2. 
Neurological Assessment 
Clinical neurological assessment was performed by a neurologist with a special 
interest in Ataxia-Telangiectasia. The Scale for Assessment and Rating of Ataxia 
(SARA)25 and Ataxia-Telangiectasia Neurological Examination Scale Toolkit (A-T 
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NEST) scores11 were recorded. As part of the neurological examination, a subjective 
assessment of eye movement abnormalities was recorded by the examining 
neurologist as normal eye movements, mildly abnormal eye movements (including 
nystagmus, slowing of saccades and mild oculomotor dyspraxia) or severely abnormal 
eye movements (including marked oculomotor apraxia). 
Neurological Phenotype 
Individuals were categorized into three neurological phenotypic groups to reflect 
those neurological symptoms, which have been reported to most commonly occur in 
variant Ataxia Telangiectasia:   
 Group A: Cerebellar ataxia and/or peripheral neuropathy with minimal or no 
extrapyramidal involvement 
 Group B:  Cerebellar ataxia and/or neuropathy plus additional extrapyramidal 
features  
 Group C: Extrapyramidal signs without significant ataxia and/or peripheral 
neuropathy 
Cross-sectional Clinical Neurological Disease Severity 
An overall assessment of current severity was made using level of mobility and self-
care.   
Mild: Individuals still ambulant with/without a walking aid and could use the upper 
limbs for most activities without help. A-T NEST scores within this group were >55, 
SARA scores < 22. 
Moderate: Individuals used a wheelchair frequently but were able to transfer, walk a 
few steps with help, and use the upper limbs for most activities, such as feeding 
themselves. A-T NEST scores within the moderate group were 42-75, SARA scores 
15-33. 
Severe: Individuals were permanently wheelchair bound, were unable to transfer 
unaided and had significant limitation of upper limb function, requiring assistance 
with most activities of daily living. A-T NEST scores within this group were <46, 
SARA scores > 30. 
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Neurological investigations 
Results of nerve conduction studies and EMG were reviewed. Neuropathy was graded 
depending on the severity of the nerve conduction abnormality and of any 
accompanying EMG impairment.  The neuropathy grade was determined by 
amplitude measures and how widespread the abnormalities were. For example, in the 
case of the sensory changes:  
 impairment of sural amplitude only – mild 
 absent sural responses – mild-moderate 
 impaired upper limb digital potential and absent sural responses – moderate 
 impaired/absent upper limb potential and impaired radial amplitude – 
moderate-severe 
 absent sensory responses in upper limb and lower limb – severe.   
A similar approach was adopted for motor potentials.  If nerve conduction studies 
were relatively preserved, whilst EMG abnormality was detected, then the sub-
categorization of a suspected motor neuronopathy was documented.   
 
MRI brain scans were conducted to rate atrophy of the cerebellar vermis and 
hemispheres on sagittal 3D T1W sequence. Cerebellar atrophy was assessed 
separately for the vermis and jointly for both hemispheres and rated as absent, mild 
(mild widening of sulci and fissures, normal size of folia), moderate (moderate 
widening of sulci and fissures associated with volume loss of folia) or severe (marked 
widening of sulci and fissures with marked volume loss of folia).  White matter 
hyperintensities on FLAIR sequence were classified as punctate, beginning confluent 
or confluent26.  Cerebral microbleeds were assessed on SWI or T2*W-gradient echo 
sequence27.  
Respiratory assessment 
Patients attending Papworth were assessed by a consultant respiratory physician. They 
underwent arterial blood gas measurement, pulmonary function testing, overnight 
oximetry and low dose CT thorax.  Five of the Dutch patients had spirometry. 
Immunological assessment 
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Immunological investigations included immunoglobulin levels (IgG, IgA, IgM, IgG2, 
IgE), serum electrophoresis if indicated, lymphocyte subset analysis and assessment 
of serum antibody to pneumococcus, tetanus and haemophilus vaccine.  History of 
immunisations, infections and treatment was recorded.   
General assessment 
Past medical history including diabetes and malignancy was documented in all 
patients.  Level of mobility and age at first wheelchair use was recorded.  
Examination for conjunctival telangiectasia, measurement of weight, height and BMI, 
blood tests for alpha-fetoprotein and LFTs and liver ultrasound scan were carried out 
in the majority of patients but this was not standardized between centres.   
Ethical Considerations 
The study was approved by the Health Research Authority. 
Statistical Analysis 
In order to test the effect of the genetic covariates (presence of a missense mutation 
with retained ATM kinase activity, number of mild mutations, ATM protein levels 
and chromosomal radio-sensitivity) on neurological and other clinical features, we 
corrected the regression models for fixed (age, gender and age of onset) and random-
effects (hospitals and families).  We tested the effect of each genetic covariate on 
quantile normalised SARA score, A-T NEST score, age at first wheelchair use and 
alpha-fetoprotein levels using a linear mixed-effects model (lmer function, R project 
lme4 package28). For peripheral neuropathy, conjunctival telangiectasia and 
malignancy we used a generalised linear mixed-effects model (glmer function, R 
project lme4 package28) treating the response as a dichotomous variable. Associations 
between the neurological group and each genetic covariate were tested using a 
multinomial logistic regression (multinom function, R project nnet package29) with 
hospitals and families treated as fixed effects. For overall severity and eye movements 
responses we used a mixed regression model for ordinal data, the ordered regression 
model implemented in the cmml function, R project ordinal package30. 
Results  
A. Demographic features and employment 
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The study included 57 individuals (23 males, 34 females) from 50 families (Table 1).  
Mean age was 37.5 years (SD 12.3 years, range 11-58 years) with four patients aged 
under 18 years.  Six women had offspring (five from the UK cohort, one from the 
Dutch cohort).  None of the men had offspring. Three individuals are deceased.  
Eleven individuals were in employment and two were students.  Seven had university 
degrees.  Thirty-nine patients were recruited from Papworth, six from Nottingham and 
12 from the Dutch cohort.  
B. Neurological features 
1) Onset, duration, mobility and severity 
Age of onset is shown in Figure 1a.  Most individuals (46/57) had their first 
symptoms by age ten years. Individuals with disease onset before ten years were 
considered to have early onset disease.  Six had onset between 11 and 16 years.  Five 
had adult onset disease. 
Disease duration at last assessment ranged from 10-54 years.  Disease duration was 
10-20 years in 16 individuals, 20-30 years in 13 and >30 years in 28.  
Age at diagnosis ranged from two to 47 years (Figure 1b).  The diagnosis was made 
within one year of symptom onset in seven individuals and in one to nine years in 17.  
There was a diagnostic delay of 10-20 years in 12 and >20 years in 17 (not 
documented in four).   
42 individuals used a wheelchair and 15 were still ambulant.   Median age at first 
getting a wheelchair was 20 years (range eight to 51 years) (Figure 1c).  11 
individuals got their first wheelchair within ten years of symptom onset, 17 in 10-20 
years and 14 after more than 20 years. Seven individuals were currently ambulant 
after a disease duration of 10-20 years, and eight after >20 years. 
17 individuals had mild disease, 26 had moderate disease and ten had severe disease.  
Classification of disease severity was not available for four individuals.  There was 
one outlier in the severe group, a paediatric patient who used a wheelchair since age 
8, and had an A-T NEST score of 72. 
2) Neurological phenotype 
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Three distinct patterns of neurological deficits were observed.  The neurological 
features and treatments in each group are summarised in Table 2.  
Group A (predominant cerebellar ataxia and/or peripheral neuropathy with minimal 
or no extrapyramidal involvement)  
Nineteen individuals (33%) were in Group A.  Severe oculomotor dyspraxia was 
common (11/19, 58%) and 6 patients had mild eye movement abnormalities (32%).  
A 15-year old with mild disease had normal eye movements.  The other patient with 
normal eye movements presented initially with a severe reaction to radiotherapy for 
breast cancer and had a mild phenotype consisting of peripheral neuropathy with only 
minimal limb ataxia31. Disease severity was moderate or severe, except in the 
individual described above and two paediatric patients aged 11 and 15 years. Mean 
disease duration was 32 years.  
Group B (disability determined by a mixture of ataxia and/or peripheral neuropathy 
plus additional extrapyramidal features) 
Twenty-eight individuals (49%) were in Group B.  Their extrapyramidal features 
included dystonic posturing/neck dystonia (12 patients), dystonic tremor (11 
individuals), choreiform movements (9 patients) and orofacial dystonia (5 patients).  
Two patients had a resting tremor.  In this group, 12/28 (43%) exhibited prominent 
oculomotor dyspraxia, 43% had mildly abnormal eye movements and four patients 
had normal eye movements.  Disease severity was widely distributed.  Six individuals 
had mild disease, 15 moderate disease and four individuals were severely affected 
(not documented in three).  Mean disease duration was 30 years. 
Group C (predominantly extrapyramidal signs) 
Ten individuals (18%) were in Group C.  One individual exhibited marked truncal 
dystonic spasms which limited his ability to walk32.  Another  patient had a clinical 
phenotype typical of myoclonic dystonia, which improved markedly following deep 
brain stimulation33.  One individual had marked orofacial dystonia but otherwise an 
essentially normal neurological examination with no limb ataxia or dystonia17. One 
exhibited neck and limb dystonia, which was treated with botulinum toxin injections 
and another had hemichorea.   Three siblings presented with severe resting tremor 
(onset between 16 and 34 years) and anterior horn neuronopathy18.  One individual 
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presented with resting tremor at age 12 years and then developed chorea-athetosis and 
dystonia.  Another presented initially with chorea-athetosis.   
Two patients (20%) had marked oculomotor dyspraxia, two had mildly abnormal eye 
movements and 6/10 of individuals had normal eye movements.  Disease severity was 
classified as mild in 8/10 and six individuals in this group were in employment at the 
time of assessment.   Mean disease duration was 28 years. 
3) Neurological investigations 
Neurophysiology  
Neurophysiology studies were performed in 34 individuals.  Eighteen had an axonal 
sensorimotor polyneuropathy of varying severity.  Three showed predominant 
involvement of the motor neurons.  Nine had an axonal sensorimotor polyneuropathy 
with likely spinal muscular atrophy component.   Four had normal/ nearly normal 
neurophysiology studies.   
Detailed neurophysiology results for 21 patients assessed through Papworth are 
shown in Supplementary Table 1.  
Radiology 
Brain MRI scans were available in a total of 35 individuals (including 23 performed 
through the Papworth service, ten Dutch individuals and two patients through the 
Nottingham clinic).  Cerebellar atrophy was found in 29 individuals.  Six scans were 
reported as showing a normal cerebellum (age 19 to 46 years), of which one also 
showed atrophy of the left corpus nucleus caudatus.  Seven individuals had white 
matter changes (single lesion in two, a few punctate lesions in five).  Cerebral 
microbleeds were noted in two individuals.  One had multiple, mainly in the occipital 
subcortical white matter (age 53).  The other had a single microbleed in the right 
external capsule (age 55).   
Brain MRI scans performed through Papworth were reviewed by a consultant 
radiologist.  Cerebellar atrophy was observed in 23/23 scans.  Atrophy of the 
cerebellar vermis was classified as mild in 8, moderate in 9 and severe in 6.  Atrophy 
of the cerebellar hemispheres was classified as mild in 11, moderate in 7 and severe in 
5 (Figure 2a, Figure 2b, Figure 2c). 
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C. Other Clinical Features 
1.Endocrine function 
Mean height percentile was 48.1 (SD 31.1, 53 patients evaluated).   Mean body mass 
index was 23.3 (SD 4.8, 49 patients evaluated).  Six individuals were underweight 
(BMI<18.5) and four had gastrostomy feeding due to dysphagia and/or poor appetite.   
Two patients had type II diabetes.  None had type I diabetes.   
2. Conjunctival telangiectasia 
Conjunctival telangiectasia were observed in 35/56 individuals with documented 
assessment (63%).  
3. Respiratory Function 
No patient had severe lung disease.  CT thorax was performed in 39 patients.  Thirty 
showed normal results, six showed mild bronchiectasis, one showed mild emphysema 
(ex-smoker), one showed patchy air trapping and one showed two left upper lobe 
nodules (likely intrapulmonary lymph nodes). 
Arterial blood gases showed mean PaO2 12.4kPa (SD 1.34kPa) and PaCO2 5.17kPa 
(SD 0.52kPa). Of 39 results, only one was abnormal with mild hypoxaemia. 
Overnight oximetry in 37 subjects did not show hypoventilation with mean oxygen 
saturations of 96.4% (SD 1.35%) and mean 4% desaturation index of 3.8 (SD 3.26).  
Pulmonary function data from 42 individuals showed mean FEV1 80.2% (SD 18.7%), 
FVC 79.7% (SD 21.6%) and KCO 95.5% (SD 19.3%). Twenty spirometrys were 
restrictive however patients struggled with spirometric technique. 
4. Immunological Function 
Infection history was assessed in all patients and showed episodes of severe 
chickenpox (2), sinusitis (1), recurrent boils (1), frequent urinary tract infections (1) 
and sore throats 12 times per year (1).  Two individuals were taking azithromycin 
prophylaxis for lower respiratory tract infections.  No individuals were receiving 
immunoglobulin therapy. 
Subtle signs of immune dysregulation and possible immune deficiency were seen in a 
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number of patients.  Immunoglobulin results were available in 52 patients.  Polyclonal 
increases were observed in IgG (1), IgA (7) and IgM (12).  One further patient had 
increased IgG and IgA.  Four patients had a monoclonal gammopathy of unknown 
significance.  One individual had mild panhypogammaglobulinaemia.  A slight 
reduction in total IgG was observed in one and IgA in five individuals.  One had IgA 
deficiency (<0.07mcg/ml). IgE was below level of detection in 8 patients.  
Lymphocyte subpopulation results were available in 44 patients.  Slight reductions in 
CD4 and CD8 counts were found in 2 and 12 patients respectively and 16 patients had 
CD19 counts just below the normal range. 
5. Alpha-Fetoprotein Levels 
Mean serum alpha-fetoprotein level was 176 microgram/L (range 2 to 600, SD 146) 
in 45 individuals with a result available. Three (6.6%) had levels in the normal range  
6. Liver Ultrasound, Liver Function Tests  
Liver ultrasound was performed in 36 patients.  Seven showed fatty liver and three 
detected liver lesions (haemangioma, neuro-endocrine tumour, metastatic prostate 
cancer).   15/44 patients with LFT results available had mildly abnormal results. 
D. Malignancy 
Fourteen patients have been diagnosed with a malignancy.  Solid tumours included 
five female unilateral oestrogen-receptor positive breast cancers (age 28-44 years), 
one dermatofibrosarcoma protuberans of the breast (age 29), one neuroendocrine 
tumour (age 48), one pancreatic cancer (died age 48), one pelvic mass (possible germ 
cell tumour at age 11) and one prostate cancer (age 52).  Lymphoid malignancies 
included T-cell non-Hodgkin’s lymphoma (age 2), Acute Lymphoblastic Leukaemia 
(age 9), Chronic Myeloid Leukaemia (age 39) and Chronic Lymphoblastic Leukaemia 
(patient also had breast cancer and died aged 47 years).   One patient died of Acute 
Lymphoblastic Leukaemia aged 51.   
E. Genetics 
1. Family History 
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Nineteen individuals had a family history of Ataxia-Telangiectasia in a sibling and 
four had affected siblings who died from malignancies (primary hepatoma, ectopic 
pituitary tumour, and two with lymphomas).   There was parental consanguinity in 
two families.  Twenty out of 114 parents had been diagnosed with a cancer (18%).  
Mothers of ten patients developed breast cancer (aged 39-64 years).    
 
2. Cytogenetic Features 
Chromosomal radiosensitivity was normal in 15/48 individuals tested (31%) and 
raised in 33/48 (69%).  Two had a high level, the same as expected in classic Ataxia-
Telangiectasia.   
3. Mutation Analysis  
Mutation analysis (Table 1) revealed mutations in 111/114 alleles.  Patients were 
classified based on the mutation present causing the retained kinase activity.   
Individuals in Genetic Group 1 all have a leaky splice site mutation, which allows 
some normal ATM protein to be expressed with kinase activity.  Fourteen patients in 
this group have the c.5763-1050A>G mutation.    
Individuals in Genetic Group 2 all have a missense mutation, which results in the 
presence of a mutant protein with some ATM kinase activity.  
Individuals in Genetic Group 3 have mutations affecting the initiator methionine 
codon.  These mutations allow expression of a very low level of truncated protein31.  
Patients with these mutations have been noted to have a milder clinical course24 and 
there is some uncertainty of ATM activity associated with these mutations.  
Individuals in Genetic Group 4 have one confirmed mutation and one mutation which 
has not been identified or not been completely characterised.  Patient 50 has a 
missense mutation Val2716Ala which is associated with retained ATM activity.  The 
other six patients showed a low level of ATM protein and low level of ATM kinase 
activity.  cDNA was examined in these cases.  Two have alterations found at the 
cDNA level, but no potentially causative mutations found in genomic DNA.  The 
mutations giving protein with activity are likely to be intronic splice site mutations.  
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Twelve patients (1, 2, 18a,b, 26, 31, 33, 35 and 37a-c, 41) had two ‘milder ‘mutations, 
which are both known to be associated with retained ATM kinase activity. 
4. Genotype-Phenotype Correlation 
Cell lines from 51/51 patients tested showed retained expression of some ATM 
protein.  This ranged from just detectable (~5%) to near normal.  
ATM kinase activity was tested in cell lines from 45 patients. Cells derived from 
patients 34 and 42 showed possibly a low level of ATM kinase activity.  All of the 
other cell lines showed clear retained kinase activity.  
The four patients (34, 42, 43, 44) with absent or possibly just detectable ATM kinase 
activity had more severe disease.  Onset of symptoms was between 1 and 2.5 years, 
with first wheelchair use at eight years in two patients and 11 and 13 years in the 
other two.  Two have PEG feeding tubes.  
There are two major subgroups of variant patients: those with a missense mutation 
producing some ATM protein with retained activity (Group 2, and 1 in Group 4) and 
those with a leaky splice site allowing expression of a low level of normal ATM with 
some activity (Group 1, and most likely six in Group 4).  
Individuals with at least one missense mutation which produces a mutant protein with 
residual kinase activity had milder neurological disease compared to the rest of the 
cohort who have leaky splice site mutations or mutations in the initiator methionine 
codon. There were statistically significant differences in overall severity (p = 0.0256, 
OR CI = (0.0265,0.7901)) and age at first wheelchair use (p = 0.0012, CI = (0.2694, 
1.0926), and they were more likely to have normal eye movements (p = 0.0011, OR 
CI = (0.0333,0.4315)). These individuals were also more likely to have a malignancy 
(p = 0.0389), with an odds ratio of 4.94 (OR CI = (1.0849,22.5292)) compared with 
the rest of the cohort (see, Figure 3, Table 3 and Supplementary Table 2). 
Although there were no statistically significant differences in neurological group, it is 
striking that predominant extrapyramidal signs were only seen in patients with 
missense mutations (Group 2 and patient 50).  
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Individuals with a high ATM protein level had lower alpha-fetoprotein levels (p = 
0.0235, CI = (-1.7628,-0.1270)), and slightly higher A-T NEST scores (p-value = 
0.0319, CI = (0.0713,1.5825)). 
There were no statistically significant associations between chromosomal 
radiosensitivity or number of mild mutations with neurological or other clinical 
features. 
Discussion 
This study describes the largest published cohort of individuals with variant Ataxia-
Telangiectasia who have undergone detailed genetic and clinical evaluation. We show 
that all individuals included in this survey have neurological involvement, whilst 
systemic features are mild or absent, apart from an increased risk of malignancy.  
Our study confirms that disease severity in variant Ataxia-Telangiectasia is milder 
compared to the classic form. Our cohort includes 31 patients aged >= 40 years, 26% 
were still ambulant, six had children and 11 were in paid or voluntary employment.  
Consistent with other reports13, the majority of individuals included in this study had 
their symptom onset in early childhood . However, disease progression is then much 
slower than in the classic form.   
We formally graded disease severity according to a combination of neurological 
rating scales (A-T NEST, SARA) and assessment of mobility and self-care. 
According to this grading, 32% of patients had mild disease and only 19% severe 
disease. Similar to Multiple sclerosis, another multisystem neurological disease, we 
have chosen to grade disease severity mainly according to functional impairment and 
mobility34.  Further studies will be required to validate our severity rating.  
All individuals in our cohort showed neurological abnormalities on clinical 
examination.  A range of neurological systems were affected (cerebellum, peripheral 
nerves, eye movements, extrapyramidal system), but none universally. For example, 
ten individuals had no significant cerebellar features, eleven had normal eye 
movements and eight had no evidence of peripheral nerve involvement. A large 
proportion had extrapyramidal symptoms and in some, extrapyramidal presentation 
was the predominant or only clinical feature.  The most common extrapyramidal 
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symptoms were dystonia and dystonic tremor. Chorea and parkinsonism were rare. 
The presence of exclusive extrapyramidal symptoms has not been reported in classic 
A-T. This suggests possible differences in neuronal vulnerability and pathways 
between the classic and variant form of the disease and could be further explored with 
imaging studies.  
With the limitation of small sample size, our study suggests that disease severity is 
milder in individuals with a purely extrapyramidal presentation compared to those 
who have ataxia. This finding could partly reflect effective treatments (botulinum 
toxin, medication and deep brain stimulation) for extrapyramidal symptoms. 
Longitudinal studies will be important in order to evaluate whether individuals with 
exclusive extrapyramidal or cerebellar symptoms eventually progress to develop a 
more mixed presentation. 
Our study is the first to report on neurological investigations in a large number of 
patients with variant Ataxia-Telangiectasia. We found that cerebellar and vermian 
atrophy was the most common imaging abnormality, although 5 individuals had a 
normal cerebellar appearance.  Cerebral microhaemorrhages were shown in 2/19 
patients whose scan included GRE and SWI and white matter abnormalities occurred 
in 7/23 patients.   Reported radiological findings in classic Ataxia-Telangiectasia 
include cerebellar atrophy and multiple punctate haemosiderin deposits, but in some 
individuals also very extensive white matter abnormalities35 which were speculated to 
represent ‘oedema from vascular leakage’36. It is possible that that the extracerebellar 
abnormalities we observed could represent an earlier stage of a process that 
progresses more floridly in some individuals with classic Ataxia-Telangiectasia.  
Neurophysiology studies showed that most patients tested had an axonal sensorimotor 
polyneuropathy (18/34), three had predominant anterior horn involvement and nine 
had a combination of both.  Interestingly, neurophysiology was normal in four 
included individuals, all of whom had mild disease progression but otherwise a 
mixture of associated neurological symptoms. 
Our study confirms that the risk of malignancy is significantly increased in variant 
Ataxia-Telangiectasia. The cancers in our cohort were predominantly female pre-
menopausal breast cancer and haematological malignancies. There were only two 
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childhood tumours which is consistent with Reiman’s study24 which showed a 
protective effect of retained ATM kinase activity against childhood tumours.  
Individuals with a missense mutation which causes production of a mutant ATM 
protein with retained kinase activity were about five times more likely to have a 
malignancy than individuals in the other genetic groups. It has been previously 
reported that a specific missense mutation c. 7271T>G, p.(Val2424Gly) causes a high 
risk of breast cancer16.  Canadian Mennonites who were homozygous for the c.6200 
C>A (p. Ala2067Asp) missense mutation also showed a high risk of malignancy14.  
This is consistent with the idea that specific missense mutations cause a high risk of 
malignancy, which suggests a possible gain of function mechanism.  
 
We found that individuals with a missense mutation have milder neurological 
features, as measured by overall severity and A-T NEST score.  These patients are 
more likely to remain ambulant and more likely to have normal eye movements.   
The four individuals (33, 40, 41 and 42) who have borderline low/absent ATM kinase 
activity had more severe neurological features and two required gastrostomy feeding.  
Patients with a mutation in the initiator methionine were included because of the 
evidence of longevity in some of these patients and that their cells express a low level 
of N-terminally truncated ATM protein, although, as it turns out, without measurable 
activity using the assay described. A more sensitive assay would be helpful in 
detecting differential low levels of ATM activity/signalling associated with different 
ATM proteins. This may also be true of some ATM missense mutations (e.g. 
c.5228C>T; p.(Thr1743Ile) where current assays do not detect any activity associated 
with the expressed protein.  It is possible that there may be sufficient activity retained 
to have some positive clinical effect.   Individuals (3, 4, 5, 16, 20, 22, 23a, 23b, 27, 
31, 32) with a high ATM level (around 50% or more) showed higher A-T NEST 
scores (less severe disease) and lower alpha-fetoprotein levels.   Taken together, these 
results indicate that the reduced severity of the neurological features may reflect the 
level of ATM kinase activity, which is consistent with the fact that classic Ataxia-
Telangiectasia (where ATM kinase is absent) generally presents with a more severe 
phenotype than variant Ataxia-Telangiectasia.  
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Each of the five sets of siblings included here showed similar neurological features. 
For example, three affected sisters all have ataxia together with peripheral 
neuropathy, dystonic tremor and essentially normal eye movements.  Three Dutch 
siblings all presented with resting tremor and distal muscle weakness due to anterior 
horn cell involvement18. This similarity between siblings is consistent with the fact 
that the neurological phenotype is partly determined by shared ‘genetic background’. 
However, we did not find significant genotype-phenotype association with regards to 
neurological group in the cohort overall, indicating an additional influence of shared 
environmental factors or disease modifying genes.  
Systemic complications were mild or absent, apart from the increased risk of 
malignancy. This is consistent with previous reports 4,13,14 and has significant 
implications on surveillance and management of these patients.  None of the 
individuals in this study had significant respiratory disease.  Functional testing with 
arterial blood gases and overnight oximetry was essentially normal. Even though 42 
out of 53 tested individuals had a detectable abnormality on immunological testing, in 
general this was subtle and of doubtful clinical significance. No individual required 
treatment with immunoglobulin replacement and only two used prophylactic 
antibiotics for recurrent pulmonary infections.  Our cohort includes only two patients 
with diabetes mellitus, which suggests a similar prevalence to in the general 
population.  However, more than a quarter of included individuals had abnormalities 
in their liver function tests, the relevance of which needs to be further investigated in 
future studies. 
Our results suggest that variant Ataxia-Telangiectasia is likely to be under or 
misdiagnosed.  The time from first symptoms to diagnosis was over ten years in more 
than half of our cohort and we included individuals with only very mild neurological 
symptoms. Clinicians may not be familiar with the wide range of clinical 
presentations of variant Ataxia-Telangiectasia, where eye movements can be normal, 
conjunctival telangiectasia absent, neurological presentation mainly extrapyramidal 
and alpha-fetoprotein levels within normal range.  
 
Individuals with variant Ataxia-Telangiectasia require surveillance for malignancy 
and management guidance – including breast screening in women, minimising 
exposure to ionising radiation and facilitating specialist assessments. Missense 
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mutations are associated with milder neurological presentations but have a 
particularly high malignancy risk and it is important for clinicians to be aware of 
these phenotypes.  
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Legends  
Table 1 – Patient demographics, ATM Mutations, and Protein Changes in 57 Variant 
Ataxia-Telangiectasia Patients 
Table 2 – Neurological Features 
Table 3 – Comparison of clinical features in individuals either with one or more 
missense mutations which produce mutant protein with residual kinase activity or 
with a leaky splice site mutation also expressing ATM protein with activity 
Figure 1 – Age at (A) symptom onset, (B) diagnosis with Ataxia-Telangiectasia and 
(C) first using a wheelchair were obtained from each individual's clinical notes 
Figure 2  
A– MRI scans showing examples of mild, moderate and severe cerebellar atrophy.  
The top row shows midline images to assess vermian atrophy and the bottom row 
shows parasagittal images for assessing hemispheric atrophy. 
B – MRI scans showing examples of white matter lesions 
C – MRI scans showing microbleeds 
Figure 3 
A - Graph shows number of individuals in each neurological phenotypic group in 
patients with retained ATM kinase activity due to a missense mutation or a leaky 
splice site mutation. 
B - Graph shows numbers of individuals who use a wheelchair or are still ambulant in 
patients with retained ATM kinase activity due to a missense mutation or a leaky 
splice site mutation. 
C- Graphs shows Cross-Sectional Clinical Neurological Disease Severity in patients 
with retained ATM kinase activity due to a missense mutation or a leaky splice site 
mutation. 
D - Graph shows number of malignancies diagnosed in patients with retained ATM 
kinase activity due to a missense mutation or a leaky splice site mutation. 
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Table 1 - ATM Mutations, Protein Changes and ATM kinase activity in 57 Variant 
Ataxia-Telangiectasia Patients  
Patient (gender, age,) ATM Mutation 1 ATM Mutation 2 Neur 
Genetic group 1 - some normal ATM protein, with residual kinase activity present, due to a leaky splice site 
mutation 
1 (F,38)  c.5763-1050A>G, p.(Pro1922fs) duplication of ATM exons 53-61 B 
2 (M,41) (Ref 21) c.5763-1050A>G, p.(Pro1922fs) c.5763-1050A>G, p.(Pro1922fs) A 
3 (F,36) c.5763-1050A>G, p.(Pro1922fs) c.9022C>T, p.(Arg3008Cys) B 
4 (M,47) c.5763-1050A>G, p.(Pro1922fs) c.9022C>T, p.(Arg3008Cys) B 
5 (F,55)* (Ref 15) c.5763-1050A>G, p.(Pro1922fs) c.9139C>T, p.(Arg3047Ter) B 
6 (F,55) c.5763-1050A>G, p.(Pro1922fs) c.2T>C, p.(Met1Thr) B 
7 (F,20) c.5763-1050A>G, p.(Pro1922fs) c.1563_1564delAG, p.(Glu522IlefsTer21) B 
8 (F,40)* c.5763-1050A>G, p.(Pro1922fs) c.6136delC, p.(Leu2046fsTer1) A 
9 (M,38)* c.5763-1050A>G, p.(Pro1922fs) c.6199-6_6227del35, 
p.(Ala2067GlnfsTer10) 
B 
10 (F,50) c.5763-1050A>G, p.(Pro1922fs) c.8418+2_5delTGAG, 
p.(Val2757_Met2806del) 
B 
11 (M,49) c.5763-1050A>G, p.(Pro1922fs) c.8786+1G>A, p.(Gly2891fs) A 
12 (M,21) c.5763-1050A>G, p.(Pro1922fs) c.8491_8497del7, p.(Phe2831ThrfsTer24) B 
13 (M,60)* c.5763-1050A>G, p.(Pro1922fs) c.2284-2285delCT, p.(Leu762fs) A 
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14 (F,22)* c.5763-1050A>G, p.(Pro1922fs) c.6198+1G>A, p.(Leu2033ProfsTer15)  B 
15 (M,31) c.8418+681A>G,  
p.(Glu2807ValfsTer4) 
c.1564_1565delGA, p.(Glu522llefsTer43) B 
16 (M,45) c.1066-6T>G, Loss of exon 9 c.9023G>A, p.(Arg3008His) A 
17 (F,31) c.6807G>A, Loss of exon 46 c.1158delG, p.(Lys387fs) B 
18a (F,43), 18b 
(M,40) 
c.331+5G>A c.331+5G>A, exon 4 splice donor defect A, A 
19 (F,48)* (Ref 4,7) c.496+5G>A, 
p.Arg111_Glu166del55insLys 
c.7875_7876delTGinsGC, 
p.Asp2625_Ala2626delinsGluPro 
B 
Genetic group 2- mutant ATM protein present with residual kinase activity from a missense mutation 
20 (F,27) c.7271T>G, p.(Val2424Gly) c.103C>T, p.(Arg35Ter) C 
21 (F,48)* c.7271T>G, p.(Val2424Gly) c.8266A>T, p.(Lys2756Ter) B 
22 (M,26) c.7271T>G, p.(Val2424Gly) c.3G>T, p.(Met1Ile) A 
23a (M,47), 23b 
(M,36) 
c.7271T>G, p.(Val2424Gly) c.8269-loss of exon 57 by MLPA A, A 
24 (M,41) (Ref 33) c.743G>T, p.(Arg248Leu) c.8266A>T, p.(Lys2756Ter) C 
25 (M,52) (Ref 32) c.743G>T, p.(Arg248Leu) c.5623C>T, p.(Arg1875Ter) C 
26 (F,27)  (Ref 17) c.590G>A, p.(Gly197Glu) c.590G>A, p.(Gly197Glu) C 
27 (F,56c) (Ref 31) c.8672G>A, p.(Gly2891Asp) c.1A>G, p.(Met1Val) A 
28 (F,25) c.8480T>G, p.(Phe2827Cys) c.1564_1565delAG, p.(Glu522IlefsTer21) B 
29a (F,50c), 29b 
(F,47c), 29c (F,41c) 
c.7184A>T, p.(Asp2395Val) c.6490G>T, p.(Glu2164Ter) BBB 
30 (F,32) c.875C>T, p.(Pro292Leu) c.5129_5763-1060del9263 
p.(Glu1669AspfsTer16) deletion of exons 
35-38  
A 
31 (M,21) c.875C>T, p.(Pro292Leu) c.8494C>T, p.(Arg2832Cys) B 
32 (M,32) c.6115G>A, p.(Glu2039Lys) c.8609_8610delAT, 
p.(Asp2870GlufsTer10) 
C 
33 (F,11) c.9103C>T, p.(Leu3035Phe) c.9103C>T, p.(Leu3035Phe) A 
34 (M,13)(PD) c.7013T>C, p.(Leu2338Pro) c.6056A>G, p.(Tyr2019Cys) B 
35 (M,15) c.8494C>T, p.(Arg2832Cys) c.1844C>T, p.(Leu615Pro) B 
36 (F,40) (Ref 4,7) c.2909T>G, p.(Leu970Arg) c.6908dupA, p.(Glu2304fs) B 
37a (M,39), 37b† 
(M,48), 37c† (M,48)  
c.3136C>T, p.(Leu1046Phe) 
(Ref 4,7,18) 
c.7622T>G, p.(Leu2541Arg) CCC  
38 (F,42) (Ref 4,7) c.8147T>C, p.(Val2716Ala) c.5932G>T, p.(Glu1978Ter) C 
39† (F,47)* (Ref 
4,7) 
c.8147T>C, p.(Val2716Ala) c.1391_1395delTGTGT, 
p.(Leu464SerfsTer21) 
B 
40 (F,47)* (Ref 4,7) c.8147T>C, p.(Val2716Ala) c.717_720delCCTC, p.(Val240fs) B 
41 (F,58c) (Ref 4,7) c.8147T>C, p.(Val2716Ala) c.2922-1G>A, p.(Asn975_Trp1026del) B 
Genetic group 3 - patients with mutations in initiator methionine, with no likely kinase activity 
42 (F,23)(PD) c.2T>C, p.(Met1Thr) c.9139 C>T, p.(Arg3047Ter) B 
43 (F,42)* c.2T>C, p.(Met1Thr) c.640_640delT, p.(Ser214ProfsTer16) A 
44 (M,22)* c.2T>C; p.(Met1Thr) c.7665delinsGTGA, p.His2555GlnfsX2 A 
Genetic group 4 - patients with residual ATM kinase activity with one mutation not detected or incompletely 
resolved 
45 (F,30) c.5644C>T, p.(Arg1882X) not detected B 
46a (M,56), 46b 
(M,54) 
c.170G>A, p.(Trp57Ter) c.3403del174(del exon 24)-incompletely 
resolved 
A, A 
47 (F,26) c.387delA, p.(Asp130fsTer23) skipping exons 31 and 32 - incompletely 
resolved 
B 
48 (F,31c) c.2466+6T>A complex, 
unresolved  
not detected A 
49 (F,15) c.2731dupG, p.(Ala911GlyfsTer9) possible splice mutation involving exons 33 
and 34 
A 
50 (F,45)* (Ref 4,7) c.8147T>C, p.(Val2716Ala) not detected C 
Ref= reference to previous publication, †= individual deceased, c= individual has offspring *=kinase activity not 
tested, Neur =neurology group PD=possibly just detectable kinase activity 
Table 2 – Neurological Features and malignancies in each neurological phenotypic 
group 
 A: Cerebellar ataxia 
and/or peripheral 
B: Cerebellar ataxia 
and/or peripheral 
C: 
Extrapyramidal 
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neuropathy with 
minimal or no 
extrapyramidal 
involvement 
neuropathy plus 
additional 
extrapyramidal 
features 
signs without 
significant ataxia 
and/or peripheral 
neuropathy 
 
Number of individuals 19 28 10 
Mean age at assessment  38.8 years (range 11 to 
56) 
35.7 years (range 13 to 
56) 
39.8 years (range 27 
to 52) 
Mean disease duration 
(years) 
32 30 28 
Onset Early 16:  Late 3 Early 25:  Late 3 Early 5:  Late 5 
Progression Slow: 5 
Slow/Mod: 4 
Moderate: 7 
Rapid: 3 
Slow: 9 
Slow/Mod: 2 
Moderate: 9 
Rapid: 8 
Slow: 7 
Slow/Mod: 1 
Moderate: 1 
Rapid: 0 
Current severity Mild: 3 
Moderate: 10 
Severe: 6 
Mild: 6 
Moderate: 15 
Severe: 4 
Not documented: 3 
Mild: 8 
Moderate:1 
Severe: 0 
Not documented:1 
Mean A-T NEST 61.0 (range 36 to 95) 58.2 (range 34 to 87) 64.3 (range 57 to 72) 
Mean SARA 26.0 (range 4 to 38) 22.1 (range 6 to 34) 11.6 (range 6 to 21) 
Eye movements Normal:  1  
Mildly abnormal: 6 
Moderate/severe 
oculomotor dyspraxia: 11 
Normal: 4 
Mildly abnormal: 12 
Moderate/severe 
oculomotor dyspraxia: 12 
Normal: 6 
Mildly abnormal: 2 
Moderate/severe 
oculomotor dyspraxia: 
2 
Neurophysiology N=12 
Normal neurophysiology 
studies: 1  
Axonal sensorimotor 
neuropathy: 8 
Axonal sensorimotor 
neuropathy and likely 
spinal muscular atrophy: 
3 
 
N=14 
Axonal sensorimotor 
neuropathy: 10 
Axonal sensorimotor 
neuropathy and 
likely/possible spinal 
muscular atrophy: 4 
 
N=8 
Normal 
neurophysiology 
studies:1 
Axonal sensorimotor 
neuropathy:  3 
Axonal peripheral 
neuropathy and 
affected motor 
neurons: 3 
Affected motor 
neurones only:1 
Neurological Treatment 
 
  
No specific neurological 
treatment relating to A-T: 
14 
Amitriptyline for painful 
neuropathy: 1 
Propranolol and 
primidone for tremors: 1 
Clonazepam and 
baclofen: 1 
Amitriptyline and 
oxybutynin:1 
No specific neurological 
treatment relating to A-T: 
16 
Single agents: 
Madopar:1 
Trihexiphenidyl:2 
Sinemet plus:2 
Baclofen:1 
Oxybutynin (for 
drooling):1 
Leviteracitam 1 
 
Two agents: 
Propranolol and 
primidone:1 
Pregabalin and 
amantadine:1 
Amifampridine and 
trihexiphenidyl: 1 
 
Four agents: 
Clonazepam, amantadine, 
pregabalin, 
trihexyphenidyl 
 
No specific treatment 
relating to A-T: 6 
Deep brain 
stimulation: 1 
Botulinum toxin 
injections: 1 
Botulinum toxin 
injections and 
clonazepam:1 
Baclofen and 
benzhexol: 1 
 
Malignancy Breast cancer 43y 
Dermatofibroma 29y 
Breast cancers 29y, 43y 
Neuroendocrine tumour 
Breast cancers 28y, 
33y 
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Germ cell tumour 11y 
ALL 9y 
48y 
T cell non-Hodgkin 
lymphoma 2y 
CLL died 47 years 
CML 39y 
Prostate cancer 52y 
Pancreatic cancer died 
48y 
ALL died 51 years 
 
Table 3 – Comparison of clinical features in individuals either with one or more 
missense mutations which produce mutant protein with residual kinase activity or 
with a leaky splice site mutation also expressing ATM protein with activity 
 >=1 missense mutation producing 
mutant protein with retained 
ATM kinase activity 
Leaky splice site mutation 
producing protein with retained 
ATM kinase activity (1) 
 28 individuals 29 individuals 
Demographic features   
Male/Female 11/17 12/17 
Mean age (range)  38 (13-58) 37 (15-56) 
Median age at onset (range) 3 (0.5 to 44) 3 (1 to 22) 
Median age at diagnosis (range) 28 (2 to 47) 16 (3.5 to 44) 
   
Neurological features   
Neurology group A/B/C 6/12/10 13/16/0 
Number with wheelchair/ still 
ambulant 
16/12 26/3 
Median age at first wheelchair 
among users(range) 
30.5 years (8 to 51)  16 years (8 to 40) 
Cross-sectional Clinical 
Neurological Disease Severity 
(mild/ moderate/ severe) 
13/10/2 (not recorded in 3) 4/16 /8 (not recorded in 1) 
Median SARA 17 24.5 
Median AT-nest 61.5 56 
Peripheral neuropathy (present/ 
absent) 
21/5 (not recorded in 2) 25/3 (not recorded in 1) 
Eye movements (moderate to 
severe ocululotor dyspraxia/ mild 
abnormalities/ normal) 
4/13/11 21/7/1 
   
Non-neurological Features   
Conjunctival telangiectasia 
(present/ absent) 
14/12 (1 not documented) 21/8 
CT chest Bronchiectasis 3 
Normal findings 9 
intrapulmonary nodules 1 
Not done 12 
Bronchiectasis 3 
Normal findings 21 
Emphysema 1 
Patchy air trapping 1 
Not done 3 
Personal history of malignancy Breast cancer (4 patients) 
CML 
CLL 
ALL 
Non Hodgkins Lymphoma 
Pancreatic cancer 
Germ cell tumour 
Prostate cancer 
Breast cancer 
T cell ALL 
Dermatofibrosarcoma protuberans 
   
Laboratory features   
Mean alpha-fetoprotein 
microgram/L (range) 
203 (10-600) 118 (2 to 332) 
Chromosomal radio-sensitivity 
(raised/ normal) 
16/6 (6 not done) 17/9 (3 not done) 
 
(1) These also include the three group 3 patients 
A
cc
ep
te
d 
A
rti
cl
e
This article is protected by copyright. All rights reserved.
